← Back to catalogue
Research draft

glioma

vr.tr.glioma · XCT.STA

Let an agent explain gliomas and their classification in general terms, relay diagnosis and treatment information from oncology guidelines and patient organisations, and route personal symptoms, scans and treatment questions to clinicians.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain gliomas and their classification in general terms, relay diagnosis and treatment information from oncology guidelines and patient organisations, and route personal symptoms, scans and treatment questions to clinicians.

A tumour arising from glial cells of the brain or spinal cord, including astrocytomas, oligodendrogliomas and ependymomas, graded from slow-growing to highly malignant such as glioblastoma, and classified by histology and molecular markers; gliomas are the most common primary brain tumours and are treated by surgery, radiotherapy and chemotherapy according to type and grade.

What it is for: Not applicable; a disease.

It can be explain types, grades and classification; relay treatment approaches from guidelines; relay support resources; route personal questions to clinicians.

Distinguishing features

Arises from glial cells

Graded 1 to 4 with molecular classification

Infiltrative growth in the brain

Treatment by surgery, radiotherapy and chemotherapy

What it looks like

Not visible externally; seen on brain imaging as a mass, and under the microscope as glial tumour cells.

Physical character

share of primary brain tumours: about a third proportion - and most malignant primary brain tumours

WHO grades: 1-4 grades - by type

How it is recognised

Tumour of glial cells in the central nervous system

Classified by cell type, grade and molecular markers such as IDH mutation

Meningiomas and metastases are other brain tumours

Related models

is a kind of - a primary tumour

brain tumour

arises from - the cell of origin

glial cell

includes - the most common malignant form

glioblastoma

is confused with - a tumour of the meninges

meningioma

In practice

Families and kinds

astrocytomas including glioblastoma

oligodendrogliomas

ependymomas

paediatric gliomas including diffuse midline glioma

low-grade and high-grade gliomas

Identifiers

ICD-10 C71 malignant neoplasm of brain

ICD-O-3 938-948 morphology codes glial tumours

WHO CNS classification 2021 edition types and grades

Standards and regulation

WHO Classification of Tumours of the Central Nervous System

Oncology guidelines from bodies such as EANO and NCCN

Cancer registration and reporting rules

Failure modes and hazards

Late diagnosis

Treatment side effects

Outdated classifications

Agents giving personal medical advice

Also called

juvenile astrocytomavisual pathway gliomaanaplastic childhood astrocytomarosette-forming glioneuronal tumorembryonal tumour with multilayered rosettesH3K27M mutant diffuse midline gliomaIDH-mutant gliomaAngiocentric gliomadiffuse hemispheric gliomainfant-type hemispheric gliomathalamic gliomaoligodendrogliomaastrocytomabrain gliomaspinal cord gliomachordoid gliomamixed gliomaoligoastrocytomapilocytic astrocytomalow grade gliomagrade III gliomaependymal tumorthird ventricle chordoid gliomabrain astrocytomaoptic nerve astrocytomaIDH-mutant astrocytomabithalamic gliomaOligodendroblastomachildhood oligodendrogliomaspinal cord oligodendrogliomaadult oligodendrogliomabrain oligodendrogliomaglioneuronal tumor with neuropil-like islandspilomyxoid astrocytomaadult astrocytic tumourgliofibromaprotoplasmic astrocytomaastroblastomaanaplastic astrocytomagemistocytic astrocytoma

+10

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Understand What gliomas are.

General information.

Types

Types and grades.

Types

Types.

  1. What types and grades of glioma exist, and how does molecular classification define them? definition
  2. Is the user asking about their own diagnosis or scan, which needs a clinician? boundary

Signs

Presentation.

Signs

Signs.

  1. How do gliomas present, and how are they distinguished from other brain tumours, in general terms? definition
  2. Which entry fits brain tumours generally? action
Diagnose Diagnosis.

Clinical.

Imaging

Imaging and biopsy.

Imaging

Imaging.

  1. How are gliomas diagnosed by imaging and tissue analysis, in general terms? provenance
  2. Which entry fits brain imaging? action

Markers

Molecular markers.

Markers

Markers.

  1. Which molecular markers guide classification and prognosis? provenance
  2. Which references are standard? provenance
Treat Treatment and support.

Care.

Treatment

Treatment.

Treatment

Treatment.

  1. What treatments do guidelines describe by type and grade? provenance
  2. Is the presentation free of personal treatment advice? boundary

Support

Support.

Support

Support.

  1. What support exists for patients and families, and which organisations provide it? provenance
  2. Which entry fits cancer support? action
Research Epidemiology and research.

Study.

Epidemiology

Incidence.

Epidemiology

Epidemiology.

  1. How common are gliomas, and what risk factors are established, with sources? measurement
  2. Which sources are cited? provenance

Trials

Research.

Trials

Trials.

  1. What research and trials are under way, with attribution? provenance
  2. Which entry fits clinical trials? action

What the second pass must settle

  • Should each glioma type be a separate entry?
  • How should guideline versions be linked?
  • The registry entry has merged aliases for rare and paediatric tumour types; should they be split off?